PreveCeutical Announces Strategic R&D Supply Agreement
Ryan Allway
September 21st, 2017
News, Top News
September 21, 2017, Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, Frankfurt: 18H) is pleased to announce that it has entered into a strategic research and development supply agreement dated effective September 18, 2017 (the “Supply Agreement”) with a licensed producer of medical cannabis (the “LP”) under Health Canada’s Access to Cannabis for Medical Purposes Regulations, whereby the LP will supply samples of cannabis-derived products and ingredient information for use by PreveCeutical in its research and development program for the commercialization of sol-gels for the nasal delivery of medical compounds, including cannabinoids (the “Sol-Gel Program”).
PreveCeutical’s Chairman and CEO, Mr. Stephen Van Deventer commented, “We are extremely pleased with the agreement between PreveCeutical and the LP. The LP is an acknowledged industry leader in Canada in terms of its high-quality, high-margin derivative products that are manufactured under rigorous standards regarding processes, testing and transparency. We believe that having access to high quality cannabis oil and dried cannabis plant extracts from the LP will greatly assist PreveCeutical with the continued development of the Sol-Gel Program.”
Commercial Terms of Supply Agreement
Under the terms of the Supply Agreement, the LP will provide the Company with prescribed strains of cannabis oil and dried cannabis plant extract along with certain ingredient and excipient specifications (the “Deliverables”). As consideration for the Deliverables and subject to acceptance by the Canadian Securities Exchange, the Company will grant to the LP:
- non-transferable options (the “Options”) to acquire that number of common shares in the capital of the Company (being 2,565,000 common shares) having an aggregate value of CAD 2 million at an exercise price equal to the closing price of PreveCeutical’s common shares on the Canadian Securities Exchange on the date of execution of the Supply Agreement, which Options will be exercisable for a period of 24 months from the effective date of the Supply Agreement;
- a right of first refusal (the “Financing ROFR”) to subscribe for the whole or a portion of any equity financing conducted by the Company for a period of 24 months from the effective date of the Supply Agreement; provided that if the LP exercises the Financing ROFR, then any Options that have not yet been exercised by the LP will expire within 15 days of the date of such exercise; and
- a right of first refusal (the “Licensing ROFR) to negotiate a non-transferable license for the non-exclusive use by the LP of the sol-gel technology developed by the Company; provided that in the event that the LP declines to exercise the Licensing ROFR, it will have the non-assignable right to receive a royalty on the gross revenues of the Company from the sale of the Company’s sol-gel technology in Australia and/or Canada to a maximum of CAD 2 million as follows:
| Aggregate Gross Revenues (CAD) | Royalty Payable (%) |
| 0 to 500,000 | 8% |
| 500,001 to 1,000,000 | 6% |
| 1,000,001 to 5,000,000 | 5% |
| 5,000,001 to 10,000,000 | 3% |
| Over 10,000,000 | 2% |
The provision of the Deliverables by the LP to the Company is conditional on the LP obtaining an export licence and complying with any other applicable regulatory requirements for the delivery of the Deliverables to Australia, as well as on the Company obtaining an import license and complying with any other regulatory requirements for the same. The Supply Agreement does not grant or transfer to the Company any intellectual property rights in the Deliverables, and vice versa does not transfer to the LP any intellectual property rights in the sol-gel technology.
Sol-Gel Nasal Delivery System
The Sol-Gel Program is focused on developing what the Company believes will be the first FDA approved, nose-to-brain delivery system of cannabinoids intended to provide relief for a range of ailments, such as pain, inflammation, seizures, and neurological disorders. The Company is seeking to design universally-patient friendly proprietary nasal formulations that can be used in children and adults alike.
PreveCeutical’s Sol-Gel Program is being conducted by the Company through UniQuest Pty Limited (“UniQuest”) pursuant to a research and development agreement dated April 22, 2017. For further information regarding the Company’s research and development agreement with UniQuest, please refer to the Company’s news release dated April 24, 2017. Any common shares of PreveCeutical issued upon the exercise of the Options will be subject to a hold period in Canada of four months and one day from the date of issuance.
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom.
For more information about PreveCeutical, please visit https://preveceutical.com/, follow us on Twitter: https://twitter.com/
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chairman & CEO
For further information, please contact:
Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Planet 13 Holdings Inc. (CSE: PLTH) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas – the entertainment capital of the world
Rubicon Holdings, Inc., a Washington State corporation, is a cannabis company focused on the United States adult use and medical marijuana markets.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
